Four Types of Post-Approval Changes in the EAEU — What Can Be Implemented Without Expert Review
One manufacturer changes the address of the batch release site. Another updates the shelf life based on new stability protocols. A third corrects a typo in the Summary of Product Characteristics. Just a few years ago, each of these actions initiated a full-scale expert assessment, consuming up to 80 business days and a substantial state fee. Backlogs in expert assessment organizations grew, while regulators processed minor amendments under the same workload as genuinely significant variations.
EAEU Council Decision No. 43 dated May 29, 2024 substantially changed this picture. It expanded the notification procedure for introducing variations to the registration dossier (RD) of a medicinal product (MP) and simultaneously implemented a versioning system for the electronic dossier. Let us analyze how the new classification is structured, what exactly has changed for Marketing Authorization Holders (MAHs), and what practical course of action to establish.
How the Old System Operated
Before the 2024 reform, the Rules for Registration and Examination of Medicinal Products for Human Use, approved by EAEU Council Decision No. 78 dated November 3, 2016 (hereinafter: the «Rules»), divided variations into Type I and Type II. Type I was considered less significant, Type II was deemed major. The procedural gap between them often proved nominal: the expert organization still performed an assessment, drafted an expert report, and the MAH waited.
The workload on the system escalated for two reasons simultaneously. The deadline for aligning national registration dossiers with EAEU requirements (December 31, 2025) forced hundreds of companies to concurrently submit dossiers for an «upgrade». In parallel, a backlog of unassessed variations accumulated under ongoing mutual recognition procedures. Expert organizations were operating at their absolute limits.
A persistent technical issue compounded the problem: the electronic dossier in eCTD (electronic Common Technical Document) format lacked a formalized versioning mechanism within the EAEU. Each document submission — whether in response to an expert query or as a variation filing — created confusion as to which package of documents was currently active. Registries and experts kept their records manually.
The New Classification and How It Works
Decision No. 43 introduced amendments to the Rules across several areas. The detailed classification of variations and the procedure for their implementation are established in Annex No. 19 to the Rules.
Four Categories Instead of Two
Variations are divided into four categories. Annex No. 19 to the Rules provides the following definitions.
Type IA. A minor variation that has only minimal impact, or no impact at all, on the quality, safety, and efficacy of the medicinal product (Paragraph 1.2.2 of Annex No. 19). The MAH is entitled to implement such a variation immediately, without waiting for any response from the authority. A notification must be submitted to all relevant authorities within 12 months from the date of implementation (Paragraph 2.1.1 of Annex No. 19).
Type IA requiring immediate notification. The same category of minor variations, but subject to a specific condition: the notification must be submitted immediately after implementation (Paragraph 2.1.2 of Annex No. 19). This applies when the change does not affect the assessment of quality or safety but is important for maintaining up-to-date registries — a change in the name of the MAH, or an update to the address of the authorized representative in a Member State.
Type IB. A minor variation that is neither a Type IA variation, nor a major Type II variation, nor an extension of registration (Paragraph 1.2.5 of Annex No. 19). This is an intermediate category with a slightly higher potential impact than Type IA. It operates on a «notify and wait» principle: the MAH submits the documentation, and if the competent authority has not sent a negative conclusion within 30 days from the date of recognizing the notification as valid, the variation is considered accepted (Paragraph 2.2.3 of Annex No. 19). Implementing the variation before the notification is accepted is prohibited. This is a fundamental distinction from Type IA (Paragraph 4.2.2.3 of Annex No. 19).
Type II. A major variation capable of exerting a significant influence on the quality, safety, or efficacy of the medicinal product (Paragraph 1.2.3 of Annex No. 19). This category requires a full preliminary expert assessment. The baseline timeline is 60 business days from the date the application is validated. In the case of changing or expanding indications for use, or when grouping complex variations, this period may be extended up to 90 business days (Paragraphs 2.3.3–2.3.4 of Annex No. 19). Implementing the variation before the expert assessment is completed is strictly prohibited.
| Type | Definition | Implementation | Notification / Authority Response |
|---|---|---|---|
| IA | Minimal or zero impact | Immediately | Notification within 12 months after implementation |
| IA (immediate) | Minimal impact, important for registries | Immediately | Notification immediately after implementation |
| IB | Minor variation, medium risk | After acceptance of notification | Authority silent for 30 days — accepted |
| II | Significant impact | After completion of expert assessment | 60–90 business days |
When Can a Variation Be Applied Immediately, and When Can It Not?
There is a practical distinction between Types IA and IB that is easy to overlook when first encountering the classification. An MAH with a Type IA variation begins manufacturing batches under the new parameters immediately after the change, with the notification submitted within the 12-month window. For Type IB, manufacturing under the new parameters can only commence after the notification has been accepted — meaning no earlier than 30 days after submission, or even later if the authority requests a revision (Paragraph 2.2.6 of Annex No. 19).
Manufacturers accustomed to the older system often conflate these two regimes. Implementing a Type IB variation before receiving tacit approval constitutes a violation of marketing authorization conditions, even if the change itself is technically flawless and thoroughly justified.
Grouping of Variations
Several variations of different types can be combined into a single application. If the grouped package contains at least one Type II variation, the entire procedure is conducted under the rules of Type II. If all variations are minor but include at least one Type IB variation, the entire procedure is processed under the rules of Type IB (Paragraph 1.7.3 of Annex No. 19).
Type IA variations for a single medicinal product from the same MAH may be combined into a single notification (Paragraph 1.7.2(a) of Annex No. 19). This allows companies to accumulate minor changes and submit them in a single package.
Practical scenario: A manufacturer updates a quality control method (Type IB), alters the secondary packaging (Type IA requiring immediate notification), and updates the address of the drug substance manufacturer (Type IA). Submitting these separately results in three procedural streams and three separate fees; grouping them produces a single application processed under the rules of Type IB.
Type IA and Type IB variations may also be incorporated into an ongoing registration renewal procedure without a separate application (Paragraph 144 of the Rules). If a renewal is already in progress, this is the most cost-effective path.
Versioning of the Electronic Dossier
Decision No. 43 introduced the concept of the «submission version (sequence) number» into Article 19 of the Rules. This is a four-digit Arabic numeral assigned to every submission: the initial dossier is designated «0000», and each subsequent submission receives the next number in sequence. A «subsequent submission» refers to a response to an expert request, an application for variations, or a supplement to a registration renewal.
The expert assessment organization can view the dossier’s history in a structured format: which version was active at the time of the previous decision, what was added, and when. This reduces discrepancies in records between the Reference State and States of Recognition. Without this technical infrastructure, the notification procedure for Types IA and IB would be practically impossible to execute — the authority must verify the declared variation against a specific, active version of the dossier.
Partial Updates to the Expert Report
Prior to Decision No. 43, expert organizations could fully revise the entire expert report during any variation procedure. The amendment to Article 62 of the Rules established a new standard: the report is updated only in those sections directly affected by the introduced variations. If an MAH has updated solely a quality control method in Module 3, the expert does not rewrite the clinical section. This can be called the «targeted update» principle.
Renewal Extensions and the Notification Procedure During the Transition Period
These notification system changes arrived at a moment of acute regulatory pressure as the deadline for aligning national registration certificates with Union requirements was fast approaching.
EAEU Council Decision No. 77 dated September 12, 2025 integrated a mechanism into Decision No. 78 to extend the validity of national registration certificates for medicinal products whose alignment procedure has been initiated but not yet finalized. According to subparagraph (e) of paragraph 2 of the Decision:
- In the Reference State: extension for the duration of the procedure, not to exceed 3 years from the date of submission of the application;
- In States of Recognition: an additional extension of not more than 2 years from the date of submission of the application to the respective authority.
This extension is not tied to a fixed calendar date — it is calculated from the actual date of application submission and depends on the specific circumstances of each product. A company that managed to submit its application by December 31, 2025 thus secured a legally protected time buffer.
The connection to the notification procedure is direct. Medicinal products undergoing alignment continue to accumulate variations within their active national dossiers. Paragraph 185 of the Rules permits introducing such changes under the national legislation of the Member States until the national registration certificate expires. The manufacturer operates in two regulatory spaces simultaneously: the EAEU notification procedure governs the EAEU-format dossier, while the rules of the respective Member State govern the source national dossier. Combining these two tracks within a single application is prohibited.
Practical Steps to Take
Audit accumulated variations. Compile a list of all planned modifications to the dossier. For each variation, determine its classification according to Annex No. 19 to the Rules (Section 1.3 and Supplement V). If the classification is uncertain, request a recommendation from the competent authority of the Reference State prior to submission (Paragraph 1.5.1 of Annex No. 19). The authority must respond within 45 business days, or up to 70 business days if the matter is referred to the Expert Committee. Erroneous classification towards a lower type — for instance, submitting a Type II variation as a Type IB — will lead to rejection of the notification.
Separate what can be implemented immediately from what must wait. Type IA variations are implemented immediately, with notifications submitted afterwards. Type IB variations can only be implemented after the notification is formally accepted by the authority. Type II variations are implemented only after the full expert assessment is completed. Premature implementation of a Type IB or Type II variation is a violation of marketing authorization conditions.
Upgrade your electronic dossier system to support eCTD versioning. All submissions following the entry into force of Decision No. 43 must be accompanied by a four-digit sequence number. Verify whether your software supports automatic generation of sequence numbers. If it does not, migrate to a compliant system before your next submission.
Plan for grouping. If a registration renewal is underway or scheduled, include accumulated Type IA and Type IB variations within it. For a set of variations of different types, check their compatibility according to Supplement III to Annex No. 19. If the types are incompatible, request consent from the Reference State authority (Paragraph 1.7.2(c) of Annex No. 19).
Check the status of your GMP obligation. If a package of documents under Paragraph 30 of the Rules was submitted instead of an EAEU GMP certificate during registration, you have a 3-year window from the conclusion of the registration procedures to undergo the inspection. Article 159 of the Rules, as amended by Decision No. 34 dated May 22, 2025, explicitly mandates suspension of the registration certificate if this 3-year term expires without a successful inspection result. Mark this deadline.
A company that structures these processes gains a real advantage: certain variations are introduced immediately without waiting for regulatory approval, scheduled renewals become strategic windows for compiled variation packages, and the overall administrative burden decreases. Those who continue submitting every minor amendment as an isolated application and do not build an organized version history of their dossiers will fall behind in both speed and cost compared with their competitors.
Regulatory Framework:
1. EAEU Council Decision No. 78 dated 03.11.2016 «On the Rules for Registration and Examination of Medicinal Products for Human Use» (as amended 26.11.2025), including Annex No. 19 «Rules for Introducing Variations to the Registration Dossier»
2. EAEU Council Decision No. 43 dated 29.05.2024 (expansion of notification procedure, implementation of dossier versioning)
3. EAEU Council Decision No. 77 dated 12.09.2025 (extension mechanism for national registration certificates during the alignment period)
4. EAEU Council Decision No. 34 dated 22.05.2025 (amendments to Articles 30 and 159 of the Rules; consequences of failing to fulfill the GMP obligation)